VEGFA and age-related macular degeneration: However, chronic use of anti‐VEGF‐A antibodies can show diminished therapeutic activity with disease progression of neovascular AMD and may induce adverse side effects in the retina, likely by inhibiting neuroprotective functions of VEGF‐A or by impairing the choriocapillaris that requires VEGF‐A for its maintenance (Marneros et al, 2005; Rofagha et al, 2013).